Effect of sulfisoxazole on the pharmacodynamics of furosemide in patients with nephrotic syndrome

J. Gorski, Y. Liu, K. Sundblad, D. C. Brater, Rajiv Agarwal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Studies have shown that substantial amounts of furosemide (F) bind to urinary protein in animals with nephrotic syndrome (NS) making the diuretic inactive. In these models, displacement of F from binding sites by sulfisoxazole (S) restores F's diuretic effectiveness. The current study was designed to determine if this occurs in humans and if so whether using S in patients with NS might be a helpful therapeutic strategy. Seven (4 males, 3 females) patient volunteers with NS between the ages of 20-60yrs participated in a randomized, placebo-controlled, crossover study investigating the effect of S on F pharmacodynamics. After achieving sodium (Na+) balance volunteers received S (2 grams Q8H × 3 doses) or placebo orally followed by an IV infusion of F (120 mg over 30min). Serum and urine samples were obtained and F, S, Na+ and potassium (K+) concentrations were determined by HPLC or flame-photometry. The results of the study are given in the Table. In conclusion, unlike the effects of S on F in animal models with NS, S does not increase the efficacy of F in patients with NS. Total Na+ Total K+ Total F Weight Excretion Excretion Excretion N (Kg) (mmol) (mmol) (mg) F alone 7 99±21 239±90 31±5 50±15 F+S 7 99±21 231±125 31±10 50±15.

Original languageEnglish
Pages (from-to)201
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume65
Issue number2
StatePublished - 1999

Fingerprint

Sulfisoxazole
Furosemide
Nephrotic Syndrome
Diuretics
Volunteers
Placebos
ethyl-2-methylthio-4-methyl-5-pyrimidine carboxylate
Photometry
Cross-Over Studies
Potassium
Animal Models
Sodium
Binding Sites
High Pressure Liquid Chromatography
Urine
Weights and Measures
Serum
Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of sulfisoxazole on the pharmacodynamics of furosemide in patients with nephrotic syndrome. / Gorski, J.; Liu, Y.; Sundblad, K.; Brater, D. C.; Agarwal, Rajiv.

In: Clinical Pharmacology and Therapeutics, Vol. 65, No. 2, 1999, p. 201.

Research output: Contribution to journalArticle

@article{063c1e3446d34b5fb9243b93c3ad4cca,
title = "Effect of sulfisoxazole on the pharmacodynamics of furosemide in patients with nephrotic syndrome",
abstract = "Studies have shown that substantial amounts of furosemide (F) bind to urinary protein in animals with nephrotic syndrome (NS) making the diuretic inactive. In these models, displacement of F from binding sites by sulfisoxazole (S) restores F's diuretic effectiveness. The current study was designed to determine if this occurs in humans and if so whether using S in patients with NS might be a helpful therapeutic strategy. Seven (4 males, 3 females) patient volunteers with NS between the ages of 20-60yrs participated in a randomized, placebo-controlled, crossover study investigating the effect of S on F pharmacodynamics. After achieving sodium (Na+) balance volunteers received S (2 grams Q8H × 3 doses) or placebo orally followed by an IV infusion of F (120 mg over 30min). Serum and urine samples were obtained and F, S, Na+ and potassium (K+) concentrations were determined by HPLC or flame-photometry. The results of the study are given in the Table. In conclusion, unlike the effects of S on F in animal models with NS, S does not increase the efficacy of F in patients with NS. Total Na+ Total K+ Total F Weight Excretion Excretion Excretion N (Kg) (mmol) (mmol) (mg) F alone 7 99±21 239±90 31±5 50±15 F+S 7 99±21 231±125 31±10 50±15.",
author = "J. Gorski and Y. Liu and K. Sundblad and Brater, {D. C.} and Rajiv Agarwal",
year = "1999",
language = "English",
volume = "65",
pages = "201",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Effect of sulfisoxazole on the pharmacodynamics of furosemide in patients with nephrotic syndrome

AU - Gorski, J.

AU - Liu, Y.

AU - Sundblad, K.

AU - Brater, D. C.

AU - Agarwal, Rajiv

PY - 1999

Y1 - 1999

N2 - Studies have shown that substantial amounts of furosemide (F) bind to urinary protein in animals with nephrotic syndrome (NS) making the diuretic inactive. In these models, displacement of F from binding sites by sulfisoxazole (S) restores F's diuretic effectiveness. The current study was designed to determine if this occurs in humans and if so whether using S in patients with NS might be a helpful therapeutic strategy. Seven (4 males, 3 females) patient volunteers with NS between the ages of 20-60yrs participated in a randomized, placebo-controlled, crossover study investigating the effect of S on F pharmacodynamics. After achieving sodium (Na+) balance volunteers received S (2 grams Q8H × 3 doses) or placebo orally followed by an IV infusion of F (120 mg over 30min). Serum and urine samples were obtained and F, S, Na+ and potassium (K+) concentrations were determined by HPLC or flame-photometry. The results of the study are given in the Table. In conclusion, unlike the effects of S on F in animal models with NS, S does not increase the efficacy of F in patients with NS. Total Na+ Total K+ Total F Weight Excretion Excretion Excretion N (Kg) (mmol) (mmol) (mg) F alone 7 99±21 239±90 31±5 50±15 F+S 7 99±21 231±125 31±10 50±15.

AB - Studies have shown that substantial amounts of furosemide (F) bind to urinary protein in animals with nephrotic syndrome (NS) making the diuretic inactive. In these models, displacement of F from binding sites by sulfisoxazole (S) restores F's diuretic effectiveness. The current study was designed to determine if this occurs in humans and if so whether using S in patients with NS might be a helpful therapeutic strategy. Seven (4 males, 3 females) patient volunteers with NS between the ages of 20-60yrs participated in a randomized, placebo-controlled, crossover study investigating the effect of S on F pharmacodynamics. After achieving sodium (Na+) balance volunteers received S (2 grams Q8H × 3 doses) or placebo orally followed by an IV infusion of F (120 mg over 30min). Serum and urine samples were obtained and F, S, Na+ and potassium (K+) concentrations were determined by HPLC or flame-photometry. The results of the study are given in the Table. In conclusion, unlike the effects of S on F in animal models with NS, S does not increase the efficacy of F in patients with NS. Total Na+ Total K+ Total F Weight Excretion Excretion Excretion N (Kg) (mmol) (mmol) (mg) F alone 7 99±21 239±90 31±5 50±15 F+S 7 99±21 231±125 31±10 50±15.

UR - http://www.scopus.com/inward/record.url?scp=33645867575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645867575&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 201

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -